Ascendis Pharma: Accelerating Commercial Momentum and Pipeline Execution Support Higher Target and Buy Rating

Analyst Yun Zhong from Wedbush maintained a Buy rating on Ascendis Pharma and increased the price target to $273.00 from $240.00.

Yun Zhong has given his Buy rating due to a combination of factors tied to Ascendis Pharma’s accelerating commercial and pipeline momentum. He highlights the strong early performance of Yorvipath, with steady increases in both treated U.S. patients and prescribing physicians, improving payer access, and an expanding international footprint that should underpin sustained revenue growth into 2026 and beyond.

In addition, he emphasizes rising confidence in an on-time FDA approval and launch of TransCon CNP for achondroplasia, supported by favorable long-term data and the company’s existing commercial platform. Higher forecasts for Yorvipath and TransCon CNP, robust expected operating cash generation and cash balances, and upside optionality from unmodeled assets such as TransCon semaglutide and TransCon anti-VEGF together support a higher price target and justify maintaining a Buy recommendation on ASND shares.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $325.00 price target.